Cargando…

Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System

COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Ebihara, Takeru, Masuda, Akitsu, Takahashi, Daisuke, Hino, Masato, Mon, Hiroaki, Kakino, Kohei, Fujii, Tsuguru, Fujita, Ryosuke, Ueda, Tadashi, Lee, Jae Man, Kusakabe, Takahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310559/
https://www.ncbi.nlm.nih.gov/pubmed/34304364
http://dx.doi.org/10.1007/s12033-021-00373-0
_version_ 1783728785822056448
author Ebihara, Takeru
Masuda, Akitsu
Takahashi, Daisuke
Hino, Masato
Mon, Hiroaki
Kakino, Kohei
Fujii, Tsuguru
Fujita, Ryosuke
Ueda, Tadashi
Lee, Jae Man
Kusakabe, Takahiro
author_facet Ebihara, Takeru
Masuda, Akitsu
Takahashi, Daisuke
Hino, Masato
Mon, Hiroaki
Kakino, Kohei
Fujii, Tsuguru
Fujita, Ryosuke
Ueda, Tadashi
Lee, Jae Man
Kusakabe, Takahiro
author_sort Ebihara, Takeru
collection PubMed
description COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody against the receptor binding domain (RBD) of the spike protein (S protein) of SARS-CoV found in SARS patients, but it was also shown to have strong affinity for that of SARS-CoV-2. In this study, we produced large amounts of three formats of CR3022 antibodies (scFv, Fab and IgG) with high purity using a silkworm-baculovirus expression vector system. Furthermore, SPR measurements showed that the affinity of those silkworm-produced IgG antibodies to S protein was almost the same as that produced in mammalian expression system. These results indicate that the silkworm-baculovirus expression system is an excellent expression system for emerging infectious diseases that require urgent demand for diagnostic agents and therapeutic agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12033-021-00373-0.
format Online
Article
Text
id pubmed-8310559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-83105592021-07-26 Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System Ebihara, Takeru Masuda, Akitsu Takahashi, Daisuke Hino, Masato Mon, Hiroaki Kakino, Kohei Fujii, Tsuguru Fujita, Ryosuke Ueda, Tadashi Lee, Jae Man Kusakabe, Takahiro Mol Biotechnol Original Paper COVID-19, caused by SARS-CoV-2, is currently spreading around the world and causing many casualties. Antibodies against such emerging infectious diseases are one of the important tools for basic viral research and the development of diagnostic and therapeutic agents. CR3022 is a monoclonal antibody against the receptor binding domain (RBD) of the spike protein (S protein) of SARS-CoV found in SARS patients, but it was also shown to have strong affinity for that of SARS-CoV-2. In this study, we produced large amounts of three formats of CR3022 antibodies (scFv, Fab and IgG) with high purity using a silkworm-baculovirus expression vector system. Furthermore, SPR measurements showed that the affinity of those silkworm-produced IgG antibodies to S protein was almost the same as that produced in mammalian expression system. These results indicate that the silkworm-baculovirus expression system is an excellent expression system for emerging infectious diseases that require urgent demand for diagnostic agents and therapeutic agents. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12033-021-00373-0. Springer US 2021-07-25 2021 /pmc/articles/PMC8310559/ /pubmed/34304364 http://dx.doi.org/10.1007/s12033-021-00373-0 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
Ebihara, Takeru
Masuda, Akitsu
Takahashi, Daisuke
Hino, Masato
Mon, Hiroaki
Kakino, Kohei
Fujii, Tsuguru
Fujita, Ryosuke
Ueda, Tadashi
Lee, Jae Man
Kusakabe, Takahiro
Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title_full Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title_fullStr Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title_full_unstemmed Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title_short Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System
title_sort production of scfv, fab, and igg of cr3022 antibodies against sars-cov-2 using silkworm-baculovirus expression system
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310559/
https://www.ncbi.nlm.nih.gov/pubmed/34304364
http://dx.doi.org/10.1007/s12033-021-00373-0
work_keys_str_mv AT ebiharatakeru productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT masudaakitsu productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT takahashidaisuke productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT hinomasato productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT monhiroaki productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT kakinokohei productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT fujiitsuguru productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT fujitaryosuke productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT uedatadashi productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT leejaeman productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem
AT kusakabetakahiro productionofscfvfabandiggofcr3022antibodiesagainstsarscov2usingsilkwormbaculovirusexpressionsystem